The EU pharmaceutical industry says it has high expectations of a soon-to-be launched pilot project that will allow drug developers to seek simultaneous scientific advice from two EU member states.
The pilot on simultaneous national scientific advice (SNSA) has the potential to strengthen early regulatory support, according to the European...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?